NCT05017025 2025-11-19
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT04106219 2025-07-23
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03898791 2021-08-05
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03955939 2020-06-01
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
Eli Lilly and Company
Phase 1 Completed